AI Article Synopsis
- The study aimed to evaluate the bioavailability of two sustained release fixed-dose combination products containing esomeprazole and domperidone in 24 healthy male volunteers.
- It utilized a randomized, balanced, open-label, 2-period cross-over design, allowing participants to receive both formulations with a 7-day wash-out period in between.
- Results showed no significant differences in pharmacokinetic parameters between the products, indicating they are bioequivalent, and both were well tolerated without adverse reactions.
Article Abstract
Objective: The study was designed to determine the relative bioavailability of two sustained release fixed dose combination (FDC) products of two manufacturers containing esomeprazole (CAS 326602-80-6) 40 mg and domperidone (CAS 57808-66-9) 30 mg in 24 healthy male volunteers. The pharmacokinetics of esomeprazole and domperidone individually after oral administration of tablet formulation has been extensively evaluated in adult volunteers. However, no published data are available regarding the combined pharmacokinetics and bioavailability of this particular FDC.
Method: The study was designed as a randomized, balanced, open-label, 2-period cross-over study. Each subject was randomized at the beginning of the study to receive either a single dose of the Test FDC or Reference FDC during Period I. Following a 7-day wash-out period, all subjects received the alternate formulation during Period II.
Results: No statistically significant differences were obtained between the two products with respect to the mean concentration-time profiles or in the pharmacokinetic parameters, including area under the serum concentration-time curve from the present study. The relative extent of absorption as assessed by the AUC ratio (Test/Reference) and C(max), the average value was found to be 1.00 +/- .09 with 90% confidence limits (C.L.) of 0.82-1.18.
Conclusion: These findings clearly indicate that the two products are bioequivalent in terms of rate and extent of drug absorption. Both preparations were well tolerated with no adverse reactions throughout the study.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-0031-1296618 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Doxycycline Postexposure Prophylaxis and Sexually Transmitted Infection Trends.
JAMA Intern Med
January 2025
San Francisco Department of Public Health, San Francisco, California.
Importance: Increasing rates of sexually transmitted infections (STIs) have been associated with rises in serious morbidity. While doxycycline postexposure prophylaxis (doxyPEP), a strategy in which individuals take doxycycline, 200 mg, after condomless sex to prevent bacterial STIs, has been shown to be efficacious in randomized clinical trials, doxyPEP's potential effect on population-level STI incidence is unknown.
Objective: To assess the association of citywide doxyPEP guideline release with reported chlamydia, gonorrhea, and early syphilis cases in men who have sex with men (MSM) and in transgender women in San Francisco, California.
Unveiling the Truth of Interactions between Microplastics and Per- and Polyfluoroalkyl Substances (PFASs) in Wastewater Treatment Plants: Microplastics as a Carrier of PFASs and Beyond.
Environ Sci Technol
January 2025
State Key Laboratory of Soil and Sustainable Agriculture, Institute of Soil Science, Chinese Academy of Sciences, Nanjing 211135, China.
Microplastics (MPs) and per- and polyfluoroalkyl substances (PFASs) are ubiquitous contaminants in environments, yet their co-occurrence and interactions remain insufficiently understood. In this study, we confirmed the concurrent presence of MPs and PFASs and their distinct distribution patterns in a wastewater treatment plant (WWTP) through a comprehensive sampling and analysis effort. Significant correlations ( < 0.
View Article and Find Full Text PDFUnveiling the Diverse Principles for Developing Sprayable Hydrogels for Biomedical Applications.
Biomacromolecules
January 2025
Center of Biomaterials, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea.
Sprayable hydrogels have emerged as a transformative innovation in biomedical technology, offering a versatile, efficient, and minimally invasive platform for various clinical applications. They form gels upon tissue contact, enabling seamless application on even complex surfaces. This property is especially useful in wound care, drug delivery, and tissue engineering, where localized and sustained release of therapeutics is essential.
View Article and Find Full Text PDFSynergistic enhancement of spinal fusion in preclinical models using low-dose rhBMP-2 and stromal vascular fraction in an injectable hydrogel composite.
Mater Today Bio
February 2025
Spine & Spinal Cord Institute, Department of Neurosurgery, College of Medicine, Yonsei University, Seoul, 03722, Republic of Korea.
Spinal fusion surgery remains a significant challenge due to limitations in current bone graft materials, particularly in terms of bioactivity, integration, and safety. This study presents an innovative approach using an injectable hydroxyapatite/β-tricalcium phosphate (HA/β-TCP) hydrogel combined with stromal vascular fraction (SVF) and low-dose recombinant human BMP-2 (rhBMP-2) to enhance osteodifferentiation and angiogenesis. Through a series of in vitro studies and preclinical models involving rats and minipigs, we demonstrated that the hydrogel system enables the sustained release of rhBMP-2, resulting in significantly improved bone density and integration, alongside reduced inflammatory responses.
View Article and Find Full Text PDFHyaluronidase-responsive hydrogel loaded with magnetic nanoparticles combined with external magnetic stimulation for spinal cord injury repair.
Mater Today Bio
February 2025
Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China.
Spinal cord injury (SCI) is a neurological condition that causes significant loss of sensory, motor, and autonomic functions below the level of injury. Current clinical treatment strategies often fail to meet expectations. Hyaluronidase is typically associated with tumor progression and bacterial infections.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!